Ginkgo Bioworks Holdings (DNA) EBT (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly EBT came in at -$76.1 million in Q1 2026, up 8.51% YoY from -$70.2 million in Q1 2025, and up 6.46% on a QoQ basis from -$81.4 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) EBT (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of EBT data on file, last reported at -$76.1 million in Q1 2026.
- Quarterly EBT rose 8.51% year-over-year to -$76.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$298.9 million (up 35.71% YoY) and the FY2025 annual result came in at -$313.6 million, up 42.72% from the prior year.
- EBT grew to -$76.1 million in Q1 2026, from -$81.4 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$56.8 million in Q3 2024 to a low of -$670.6 million in Q2 2022.
- A 5-year average of -$232.0 million and a median of -$173.2 million in 2023 frame the typical range for EBT.
- The widest YoY moves for EBT: up 88.3% in 2022, down 1121.63% in 2022.
- Tracing DNA's EBT over 5 years: stood at -$187.8 million in 2022, then fell by 12.8% to -$211.9 million in 2023, then soared by 49.1% to -$107.9 million in 2024, then increased by 24.54% to -$81.4 million in 2025, then gained by 6.46% to -$76.1 million in 2026.
- The last three EBT figures came in at -$76.1 million (Q1 2026), -$81.4 million (Q4 2025), and -$80.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -57.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.19 Mn |
| Mar 31, 2026 | -76.14 Mn |
| Dec 31, 2025 | -81.39 Mn |
| Sep 30, 2025 | -80.75 Mn |
| Jun 30, 2025 | -60.58 Mn |
| Mar 31, 2025 | -83.22 Mn |
| Dec 31, 2024 | -107.86 Mn |
| Sep 30, 2024 | -56.78 Mn |
| Jun 30, 2024 | -216.99 Mn |
| Mar 31, 2024 | -165.88 Mn |
| Dec 31, 2023 | -211.89 Mn |
| Sep 30, 2023 | -302.91 Mn |
| Jun 30, 2023 | -173.25 Mn |
| Mar 31, 2023 | -204.89 Mn |
| Dec 31, 2022 | -187.85 Mn |
| Sep 30, 2022 | -670.16 Mn |
| Jun 30, 2022 | -670.62 Mn |
| Mar 31, 2022 | -592.78 Mn |
| Dec 31, 2021 | -1.61 Bn |
| Sep 30, 2021 | -102.61 Mn |